Viking Therapeutics earnings were -$171.5M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest VKTX earnings report on Jun 30, 2025 announced Q2 2025 earnings of -$65.6M, up 43.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, VKTX reported annual earnings of -$110.0M, with 28% growth.
Viking Therapeutics Earnings Reports & History FAQ
What were Viking Therapeutics's earnings last quarter?
On VKTX's earnings call on Invalid Date, Viking Therapeutics (NASDAQ: VKTX) reported Q2 2025 earnings per share (EPS) of -$0.58, up 190% year over year. Total VKTX earnings for the quarter were -$65.56 million. In the same quarter last year, Viking Therapeutics's earnings per share (EPS) was -$0.20.
Is Viking Therapeutics profitable or losing money?
As of the last Viking Therapeutics earnings report, Viking Therapeutics is currently losing money. Viking Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2025 was -$171.55 million, a 77.32% increase year over year.
What was VKTX's earnings growth in the past year?
As of Viking Therapeutics's earnings date in Invalid Date, Viking Therapeutics's earnings has grown year over year. VKTX earnings in the past year totalled -$171.55 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.